208 related articles for article (PubMed ID: 16423426)
1. Expression of matrix metalloproteinases 7 and 9 in non-small cell lung cancer. Relation to clinicopathological factors, beta-catenin and prognosis.
Leinonen T; Pirinen R; Böhm J; Johansson R; Ropponen K; Kosma VM
Lung Cancer; 2006 Mar; 51(3):313-21. PubMed ID: 16423426
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
Cox G; Jones JL; O'Byrne KJ
Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
[TBL] [Abstract][Full Text] [Related]
3. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
4. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
Takemoto N; Tada M; Hida Y; Asano T; Cheng S; Kuramae T; Hamada J; Miyamoto M; Kondo S; Moriuchi T
Lung Cancer; 2007 Dec; 58(3):376-83. PubMed ID: 17714826
[TBL] [Abstract][Full Text] [Related]
5. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer.
Shou Y; Hirano T; Gong Y; Kato Y; Yoshida K; Ohira T; Ikeda N; Konaka C; Ebihara Y; Zhao F; Kato H
Br J Cancer; 2001 Nov; 85(11):1706-12. PubMed ID: 11742492
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
7. Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.
Safranek J; Pesta M; Holubec L; Kulda V; Dreslerova J; Vrzalova J; Topolcan O; Pesek M; Finek J; Treska V
Anticancer Res; 2009 Jul; 29(7):2513-7. PubMed ID: 19596921
[TBL] [Abstract][Full Text] [Related]
8. [Expressions of vascular endothelial growth factor C and matrix metalloproteinases-2 and prognosis of non-small cell lung carcinoma].
Zhang HZ; Wei YP; Li HG; Wang M; Liu JG; Wu C
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Sep; 26(9):1307-10. PubMed ID: 16982442
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-13 expression is associated with bone marrow microinvolvement and prognosis in non-small cell lung cancer.
Hsu CP; Shen GH; Ko JL
Lung Cancer; 2006 Jun; 52(3):349-57. PubMed ID: 16569461
[TBL] [Abstract][Full Text] [Related]
10. Wnt1 overexpression promotes tumour progression in non-small cell lung cancer.
Huang CL; Liu D; Ishikawa S; Nakashima T; Nakashima N; Yokomise H; Kadota K; Ueno M
Eur J Cancer; 2008 Nov; 44(17):2680-8. PubMed ID: 18790633
[TBL] [Abstract][Full Text] [Related]
11. CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma.
Kosunen A; Pirinen R; Ropponen K; Pukkila M; Kellokoski J; Virtaniemi J; Sironen R; Juhola M; Kumpulainen E; Johansson R; Nuutinen J; Kosma VM
Oral Oncol; 2007 Jan; 43(1):51-9. PubMed ID: 16798062
[TBL] [Abstract][Full Text] [Related]
12. Expression and clinical significance of matrix metalloproteinase (MMP)-26 protein in non-small cell lung cancer.
Li L; Mei TH; Zhou XD; Zhang XG
Ai Zheng; 2009 Jan; 28(1):60-3. PubMed ID: 19448419
[TBL] [Abstract][Full Text] [Related]
13. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer.
Lin TS; Chiou SH; Wang LS; Huang HH; Chiang SF; Shih AY; Chen YL; Chen CY; Hsu CP; Hsu NY; Chou MC; Kuo SJ; Chow KC
Oncol Rep; 2004 Oct; 12(4):717-23. PubMed ID: 15375490
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer.
Passlick B; Sienel W; Seen-Hibler R; Wöckel W; Thetter O; Mutschler W; Pantel K
Clin Cancer Res; 2000 Oct; 6(10):3944-8. PubMed ID: 11051242
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of matrix metalloproteinase-7 (MMP-7) correlates with tumor proliferation, and a poor prognosis in non-small cell lung cancer.
Liu D; Nakano J; Ishikawa S; Yokomise H; Ueno M; Kadota K; Urushihara M; Huang CL
Lung Cancer; 2007 Dec; 58(3):384-91. PubMed ID: 17728005
[TBL] [Abstract][Full Text] [Related]
16. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
[TBL] [Abstract][Full Text] [Related]
17. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.
Horiuchi S; Yamamoto H; Min Y; Adachi Y; Itoh F; Imai K
J Pathol; 2003 Aug; 200(5):568-76. PubMed ID: 12898592
[TBL] [Abstract][Full Text] [Related]
18. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival.
Zheng S; Chang Y; Hodges KB; Sun Y; Ma X; Xue Y; Williamson SR; Lopez-Beltran A; Montironi R; Cheng L
Anticancer Res; 2010 Mar; 30(3):713-8. PubMed ID: 20392988
[TBL] [Abstract][Full Text] [Related]
19. Versican in nonsmall cell lung cancer: relation to hyaluronan, clinicopathologic factors, and prognosis.
Pirinen R; Leinonen T; Böhm J; Johansson R; Ropponen K; Kumpulainen E; Kosma VM
Hum Pathol; 2005 Jan; 36(1):44-50. PubMed ID: 15712181
[TBL] [Abstract][Full Text] [Related]
20. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
